N-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine

Sale

N-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine

Original price was: $34.00.Current price is: $23.00.

N-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine is a PAICS pathway inhibitor. It plays a critical role in research targeting SAICAR accumulation, purine metabolism disorders, and cellular metabolic stress responses.

EMI starting from $0.00/month - View Plans
Compare
Category: Tag:

Description

Product Description

N-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine (CAS No. 306748-45-8) is a synthetic dipeptide-like compound designed for biochemical and molecular biology research. Its primary function is the interference with the PAICS protein, an enzyme involved in purine nucleotide biosynthesis.

About PAICS

  • PAICS (phosphoribosylaminoimidazole carboxylase / phosphoribosylaminoimidazole succinocarboxamide synthetase) is a key bifunctional enzyme in the de novo purine biosynthesis pathway.

  • It catalyzes crucial steps leading to IMP (inosine monophosphate), the precursor of AMP and GMP.

  • Dysregulation of PAICS activity can lead to accumulation of metabolic intermediates such as SAICAR (succinylaminoimidazole carboxamide ribose-5’-phosphate) and SAICAr (its riboside form).

Function of This Compound

This compound directly interferes with PAICS enzymatic activity, resulting in:

  • Reduced SAICAR accumulation: prevents excessive buildup of this intermediate, which is linked to altered cellular signaling and stress pathways.

  • Stabilization of purine pools: ensures a more balanced metabolic state in experimental models.

  • Utility in disease modeling: accumulation of SAICAR has been implicated in oncogenic signaling, metabolic syndromes, and neurodevelopmental disorders.

Research Relevance

  • Cancer metabolism: SAICAR accumulation activates PKM2 (pyruvate kinase M2), enhancing glycolytic flux in tumor cells. Inhibiting SAICAR buildup via PAICS interference may help dissect metabolic vulnerabilities in cancer.

  • Rare genetic diseases: Inborn errors of purine metabolism often involve accumulation of intermediates like SAICAr. This compound provides a research tool to study such disorders.

  • Drug discovery: Serves as a lead compound or biochemical probe for identifying novel PAICS-targeted therapeutics.

  • Metabolomics: Facilitates analysis of purine-related fluxes in cellular models.

By interfering with purine biosynthesis, N-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine becomes a valuable tool in understanding how nucleotide metabolism impacts disease progression and cellular homeostasis.


Product Specifications

ParameterDetails
Product NameN-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine
CAS Number306748-45-8
Chemical ClassSynthetic dipeptide analogue
Molecular TargetPAICS protein (purine biosynthesis enzyme)
FunctionReduces SAICAR and SAICAr accumulation
MechanismEnzyme interference / pathway inhibition
Biological PathwayDe novo purine nucleotide biosynthesis
ApplicationsCancer metabolism, metabolic disease models, biochemical pathway studies
AppearanceWhite to off-white crystalline powder
Purity≥98% (HPLC)
SolubilityWater, DMSO
Storage Conditions-20°C, sealed, protect from light
Shelf Life≥12 months under recommended storage
QC TestsHPLC, NMR, Mass spectrometry

Mechanism of Action

The mechanism of action of N-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine centers on its interaction with PAICS, thereby altering purine biosynthesis.

1. PAICS Enzyme Function

  • PAICS catalyzes two sequential steps in the purine synthesis pathway:

    • Conversion of CAIR (carboxyaminoimidazole ribonucleotide) to SAICAR.

    • Cyclization of SAICAR toward AICAR formation, leading eventually to IMP.

2. Compound Interference

  • This compound acts as a molecular mimic, disrupting PAICS catalytic function.

  • The result is suppressed formation of SAICAR, and consequently reduced SAICAr accumulation.

3. Downstream Consequences

  • Inhibition of PKM2 activation: SAICAR normally binds to PKM2, promoting glycolysis in proliferating tumor cells. Blocking SAICAR prevents this pro-cancerous effect.

  • Altered nucleotide balance: Lower SAICAR prevents toxic accumulation, leading to more controlled nucleotide synthesis.

  • Metabolic remodeling: Cells under experimental treatment exhibit changes in energy metabolism, growth rates, and biosynthetic balance.

4. Research Outcomes

  • Cancer Research: Understanding metabolic checkpoints in tumor growth.

  • Genetic Studies: Modeling rare metabolic disorders caused by abnormal SAICAr levels.

  • Therapeutic Design: Identifying opportunities for developing PAICS inhibitors.

    n-[(6s)-6-carboxy-6-(glycylamino)hexanoyl]-d-alanyl-d-alanine


Side Effects

This compound is for research use only, and not approved for therapeutic application. While no human clinical safety data exists, potential experimental side effects can be inferred:

  • Metabolic Stress in Cells: Inhibition of purine biosynthesis can cause reduced proliferation in rapidly dividing cells.

  • Cytotoxicity in Tumor Models: May induce apoptosis when nucleotide pools are imbalanced.

  • Cell Cycle Alterations: Experimental models may show G1/S arrest due to reduced nucleotide supply.

  • Neurotoxicity Potential: Since purine metabolism impacts neuronal development, improper dosing could affect neuronal models.

Laboratory Safety Notes

  • Handle under BSL-2 conditions.

  • Wear gloves, lab coat, and protective eyewear.

  • Dispose of waste according to institutional biosafety guidelines.


Disclaimer

This product is intended for laboratory research use only. Not for diagnostic, clinical, or therapeutic purposes.


Keywords

PAICS inhibitor, purine biosynthesis inhibitor, SAICAR accumulation, SAICAr reduction, cancer metabolism probe, metabolic disorder research, nucleotide metabolism, CAS 306748-45-8.Freeze-dried Peptide Powder-Manufacturer-Wholesaler


Shipping Guarantee

  • Tax-inclusive shipping with customs clearance provided.

  • Any shipping damage or loss is fully compensated.


Transaction Guarantee

  • Supports T/T, PayPal, cryptocurrency, and secure payment methods.

  • Contact our sales team for special arrangements.

Additional information

Weight0.8 kg
Dimensions56 × 38 × 56 cm

Reviews

There are no reviews yet.

Be the first to review “N-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine”

Your email address will not be published. Required fields are marked *

1. What is N-[(6S)-6-Carboxy-6-(glycylamino)hexanoyl]-D-alanyl-D-alanine?

A synthetic dipeptide analogue that interferes with PAICS activity.

2. What is its CAS number?

CAS No. 306748-45-8.

3. What biological pathway does it affect?

The de novo purine biosynthesis pathway.

4. What is PAICS?

A bifunctional enzyme catalyzing two steps in IMP synthesis.

5. What is SAICAR?

Succinylaminoimidazole carboxamide ribose-5’-phosphate, an intermediate in purine biosynthesis.

6. How does this compound affect SAICAR?

It reduces SAICAR accumulation by interfering with PAICS function.

7. What diseases are linked to SAICAR accumulation?

Cancer metabolism, certain rare metabolic disorders, and potential neurological conditions.

8. What are its applications in research?

Used in cancer biology, metabolic pathway studies, and drug discovery.

9. Is it safe for human use?

No, it is for research use only.

10. What is its purity?

≥98%, verified by HPLC.

11. How should it be stored?

At -20°C, protected from moisture and light.

12. Can it be used in in vivo studies?

Yes, in preclinical models, but under strict laboratory protocols.


EMI Options

Select at least 2 products
to compare